Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review

Michael Yamakawa, Susan J. Doh, Samuel M. Santosa, Mario Montana, Ellen C. Qin, Hyunjoon Kong, Kyu Yeon Han, Charles Yu, Mark I. Rosenblatt, Andrius Kazlauskas, Jin Hong Chang, Dimitri T. Azar

Research output: Contribution to journalReview article

Abstract

In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro-lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA-approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA-approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.

Original languageEnglish (US)
Pages (from-to)1769-1798
Number of pages30
JournalMedicinal Research Reviews
Volume38
Issue number6
DOIs
StatePublished - Nov 2018

Fingerprint

Lymphangiogenesis
Learning
Pharmaceutical Preparations
Vascular Endothelial Growth Factor C
Nanotechnology
Lymphatic Vessels
Lymphedema
Heel
Graft Rejection
Lymph
Therapeutics
Biomarkers
Pathology
Neoplasm Metastasis
Transplants
Research
Neoplasms

Keywords

  • angiogenesis
  • lymphangiogenesis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Yamakawa, M., Doh, S. J., Santosa, S. M., Montana, M., Qin, E. C., Kong, H., ... Azar, D. T. (2018). Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review. Medicinal Research Reviews, 38(6), 1769-1798. https://doi.org/10.1002/med.21496

Potential lymphangiogenesis therapies : Learning from current antiangiogenesis therapies—A review. / Yamakawa, Michael; Doh, Susan J.; Santosa, Samuel M.; Montana, Mario; Qin, Ellen C.; Kong, Hyunjoon; Han, Kyu Yeon; Yu, Charles; Rosenblatt, Mark I.; Kazlauskas, Andrius; Chang, Jin Hong; Azar, Dimitri T.

In: Medicinal Research Reviews, Vol. 38, No. 6, 11.2018, p. 1769-1798.

Research output: Contribution to journalReview article

Yamakawa, M, Doh, SJ, Santosa, SM, Montana, M, Qin, EC, Kong, H, Han, KY, Yu, C, Rosenblatt, MI, Kazlauskas, A, Chang, JH & Azar, DT 2018, 'Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review', Medicinal Research Reviews, vol. 38, no. 6, pp. 1769-1798. https://doi.org/10.1002/med.21496
Yamakawa, Michael ; Doh, Susan J. ; Santosa, Samuel M. ; Montana, Mario ; Qin, Ellen C. ; Kong, Hyunjoon ; Han, Kyu Yeon ; Yu, Charles ; Rosenblatt, Mark I. ; Kazlauskas, Andrius ; Chang, Jin Hong ; Azar, Dimitri T. / Potential lymphangiogenesis therapies : Learning from current antiangiogenesis therapies—A review. In: Medicinal Research Reviews. 2018 ; Vol. 38, No. 6. pp. 1769-1798.
@article{27e9202654b040ccbb3d17c99ac97817,
title = "Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review",
abstract = "In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro-lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA-approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA-approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.",
keywords = "angiogenesis, lymphangiogenesis",
author = "Michael Yamakawa and Doh, {Susan J.} and Santosa, {Samuel M.} and Mario Montana and Qin, {Ellen C.} and Hyunjoon Kong and Han, {Kyu Yeon} and Charles Yu and Rosenblatt, {Mark I.} and Andrius Kazlauskas and Chang, {Jin Hong} and Azar, {Dimitri T.}",
year = "2018",
month = "11",
doi = "10.1002/med.21496",
language = "English (US)",
volume = "38",
pages = "1769--1798",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Potential lymphangiogenesis therapies

T2 - Learning from current antiangiogenesis therapies—A review

AU - Yamakawa, Michael

AU - Doh, Susan J.

AU - Santosa, Samuel M.

AU - Montana, Mario

AU - Qin, Ellen C.

AU - Kong, Hyunjoon

AU - Han, Kyu Yeon

AU - Yu, Charles

AU - Rosenblatt, Mark I.

AU - Kazlauskas, Andrius

AU - Chang, Jin Hong

AU - Azar, Dimitri T.

PY - 2018/11

Y1 - 2018/11

N2 - In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro-lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA-approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA-approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.

AB - In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro-lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA-approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA-approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.

KW - angiogenesis

KW - lymphangiogenesis

UR - http://www.scopus.com/inward/record.url?scp=85043461227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043461227&partnerID=8YFLogxK

U2 - 10.1002/med.21496

DO - 10.1002/med.21496

M3 - Review article

C2 - 29528507

AN - SCOPUS:85043461227

VL - 38

SP - 1769

EP - 1798

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

IS - 6

ER -